Home LiteratureArticle Details
PMID: 21787441 Published · epublish English Journal Article Research Support, Non-U.S. Gov't Review

Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction.

Breast cancer research : BCR ·Vol. 13 ·No. 3 ·2011-06-27 ·Pages 212

Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS

Abstract

Breast cancer comprises a collection of diseases with distinctive clinical, histopathological, and molecular features. Importantly, tumors with similar histological features may display disparate clinical behaviors. Gene expression profiling using microarray technologies has improved our understanding of breast cancer biology and has led to the development of a breast cancer molecular taxonomy and of multigene 'signatures' to predict outcome and response to systemic therapies. The use of these prognostic and predictive signatures in routine clinical decision-making remains controversial. Here, we review the clinical relevance of microarray-based profiling of breast cancer and discuss its impact on patient management.

MeSH Terms
Breast Neoplasms/classification,genetics,pathology Female Gene Expression Profiling Gene Expression Regulation, Neoplastic Humans Oligonucleotide Array Sequence Analysis/methods Treatment Outcome
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Colombo Pierre-Emmanuel
Molecular Pathology Team, Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK.
Milanezi Fernanda
Weigelt Britta
Reis-Filho Jorge S
References (111)
111 references, click to expand
  1. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade.
    J Clin Oncol. 2007 Apr 1;25(10):1239-46 PMID: 17401012
  2. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer.
    Clin Cancer Res. 2007 Jul 15;13(14):4078-82 PMID: 17634532
  3. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.
    J Natl Cancer Inst. 2011 Apr 20;103(8):662-73 PMID: 21421860
  4. Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation.
    Clin Cancer Res. 2010 Jan 15;16(2):681-90 PMID: 20068102
  5. Challenges in projecting clustering results across gene expression-profiling datasets.
    J Natl Cancer Inst. 2007 Nov 21;99(22):1715-23 PMID: 18000217
  6. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer.
    Breast Cancer Res Treat. 2010 Apr;120(3):655-61 PMID: 20204499
  7. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer.
    Nat Med. 2010 Feb;16(2):214-8 PMID: 20098429
  8. Identification of molecular apocrine breast tumours by microarray analysis.
    Oncogene. 2005 Jul 7;24(29):4660-71 PMID: 15897907
  9. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
    N Engl J Med. 2004 Dec 30;351(27):2817-26 PMID: 15591335
  10. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Lancet Oncol. 2007 Dec;8(12):1079-1087 PMID: 18042430
  11. Origins of breast cancer subtypes and therapeutic implications.
    Nat Clin Pract Oncol. 2007 Sep;4(9):516-25 PMID: 17728710
  12. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
    J Natl Cancer Inst. 2011 Feb 2;103(3):264-72 PMID: 21191116
  13. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
    J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 PMID: 16478745
  14. Concordance among gene-expression-based predictors for breast cancer.
    N Engl J Med. 2006 Aug 10;355(6):560-9 PMID: 16899776
  15. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
    Lancet. 2003 Aug 2;362(9381):362-9 PMID: 12907009
  16. Do predictive signatures really predict response to cancer chemotherapy?
    Cell Cycle. 2010 Dec 15;9(24):4836-40 PMID: 21150277
  17. The Gene expression Grade Index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial.
    BMC Med Genomics. 2009 Jul 02;2:40 PMID: 19573224
  18. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.
    J Clin Oncol. 2006 Apr 20;24(12):1839-45 PMID: 16622258
  19. Prediction of docetaxel response in human breast cancer by gene expression profiling.
    J Clin Oncol. 2005 Jan 20;23(3):422-31 PMID: 15659489
  20. HOXB13-to-IL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrent breast cancer: a retrospective study.
    J Clin Oncol. 2007 Feb 20;25(6):662-8 PMID: 17308270
  21. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.
    Clin Cancer Res. 2008 Aug 15;14(16):5158-65 PMID: 18698033
  22. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.
    Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3738-43 PMID: 15701700
  23. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
    J Clin Oncol. 2007 Nov 20;25(33):5287-312 PMID: 17954709
  24. Repeated observation of breast tumor subtypes in independent gene expression data sets.
    Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 PMID: 12829800
  25. Clinical application of the 70-gene profile: the MINDACT trial.
    J Clin Oncol. 2008 Feb 10;26(5):729-35 PMID: 18258980
  26. Histological and molecular types of breast cancer: is there a unifying taxonomy?
    Nat Rev Clin Oncol. 2009 Dec;6(12):718-30 PMID: 19942925
  27. Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials.
    Lancet Oncol. 2010 Apr;11(4):358-65 PMID: 20189874
  28. Gene expression profiling predicts clinical outcome of breast cancer.
    Nature. 2002 Jan 31;415(6871):530-6 PMID: 11823860
  29. Breast cancer prognostic classification in the molecular era: the role of histological grade.
    Breast Cancer Res. 2010;12(4):207 PMID: 20804570
  30. Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.
    Cancer. 2010 Nov 15;116(22):5161-7 PMID: 20665886
  31. Outcome signature genes in breast cancer: is there a unique set?
    Bioinformatics. 2005 Jan 15;21(2):171-8 PMID: 15308542
  32. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis.
    Nat Rev Cancer. 2007 Oct;7(10):791-9 PMID: 17851544
  33. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients.
    Breast Cancer Res. 2006;8(3):R25 PMID: 16737553
  34. A robust classifier of high predictive value to identify good prognosis patients in ER-negative breast cancer.
    Breast Cancer Res. 2008;10(4):R73 PMID: 18755024
  35. Are clusters found in one dataset present in another dataset?
    Biostatistics. 2007 Jan;8(1):9-31 PMID: 16613834
  36. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
    J Clin Oncol. 2006 Aug 10;24(23):3726-34 PMID: 16720680
  37. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen.
    BMC Genomics. 2008 May 22;9:239 PMID: 18498629
  38. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
    Proc Natl Acad Sci U S A. 2010 Jun 1;107(22):10208-13 PMID: 20479250
  39. The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis.
    Breast Cancer Res. 2006;8(3):R32 PMID: 16790077
  40. Stromal gene expression predicts clinical outcome in breast cancer.
    Nat Med. 2008 May;14(5):518-27 PMID: 18438415
  41. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  42. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.
    Breast Cancer Res. 2010;12(5):R68 PMID: 20813035
  43. Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.
    Lancet Oncol. 2009 Nov;10(11):1070-6 PMID: 19801202
  44. Molecular classification of tamoxifen-resistant breast carcinomas by gene expression profiling.
    J Clin Oncol. 2005 Feb 1;23(4):732-40 PMID: 15681518
  45. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells.
    Cell Stem Cell. 2010 Sep 3;7(3):403-17 PMID: 20804975
  46. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.
    J Clin Oncol. 2010 Apr 10;28(11):1829-34 PMID: 20212256
  47. Rules of evidence for cancer molecular-marker discovery and validation.
    Nat Rev Cancer. 2004 Apr;4(4):309-14 PMID: 15057290
  48. Expression of concern--validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
    Lancet Oncol. 2010 Sep;11(9):813-4 PMID: 20667781
  49. Comparison of prognostic gene expression signatures for breast cancer.
    BMC Genomics. 2008 Aug 21;9:394 PMID: 18717985
  50. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.
    J Clin Oncol. 2005 Oct 10;23(29):7265-77 PMID: 16145055
  51. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers.
    Nat Med. 2009 Aug;15(8):907-13 PMID: 19648928
  52. Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial.
    Lancet Oncol. 2007 Dec;8(12):1071-1078 PMID: 18024211
  53. Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer--comparison between Adjuvant!, St Gallen, and a novel risk algorithm used in the prospective randomized Node-Negative-Breast Cancer-3 (NNBC-3) trial.
    Ann Oncol. 2009 Feb;20(2):258-64 PMID: 18824499
  54. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis.
    Breast Cancer Res Treat. 2009 Sep;117(2):273-80 PMID: 18815879
  55. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series.
    Clin Cancer Res. 2007 Jun 1;13(11):3207-14 PMID: 17545524
  56. Prediction of cancer outcome with microarrays: a multiple random validation strategy.
    Lancet. 2005 Feb 5-11;365(9458):488-92 PMID: 15705458
  57. Genetic interactions in cancer progression and treatment.
    Cell. 2011 Apr 1;145(1):30-8 PMID: 21458666
  58. Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry.
    Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S5 PMID: 21172089
  59. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
    Ann Oncol. 2011 Jul;22(7):1561-1570 PMID: 21135055
  60. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer.
    Lancet. 2005 Feb 19-25;365(9460):671-9 PMID: 15721472
  61. Extracellular matrix signature identifies breast cancer subgroups with different clinical outcome.
    J Pathol. 2008 Feb;214(3):357-67 PMID: 18044827
  62. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures.
    Breast Cancer Res. 2008;10(4):R65 PMID: 18662380
  63. Supervised risk predictor of breast cancer based on intrinsic subtypes.
    J Clin Oncol. 2009 Mar 10;27(8):1160-7 PMID: 19204204
  64. Histological types of breast cancer: how special are they?
    Mol Oncol. 2010 Jun;4(3):192-208 PMID: 20452298
  65. Genomic index of sensitivity to endocrine therapy for breast cancer.
    J Clin Oncol. 2010 Sep 20;28(27):4111-9 PMID: 20697068
  66. Molecular classification of breast cancer: limitations and potential.
    Oncologist. 2006 Sep;11(8):868-77 PMID: 16951390
  67. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.
    Nat Med. 2009 Jan;15(1):68-74 PMID: 19122658
  68. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
    J Clin Oncol. 2004 Jun 15;22(12):2284-93 PMID: 15136595
  69. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer.
    J Clin Oncol. 2006 Oct 1;24(28):4611-9 PMID: 17008703
  70. Introducing molecular subtyping of breast cancer into the clinic?
    J Clin Oncol. 2009 Mar 10;27(8):1153-4 PMID: 19204193
  71. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines.
    Breast Cancer Res Treat. 2010 Jun;121(2):301-9 PMID: 19603265
  72. Triple-negative breast cancer.
    N Engl J Med. 2010 Nov 11;363(20):1938-48 PMID: 21067385
  73. Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers.
    J Clin Oncol. 2006 Apr 10;24(11):1656-64 PMID: 16505416
  74. Mammary development meets cancer genomics.
    Nat Med. 2009 Aug;15(8):842-4 PMID: 19661985
  75. Molecular profiling: moving away from tumor philately.
    Sci Transl Med. 2010 Sep 1;2(47):47ps43 PMID: 20811040
  76. Clinical implementation of the intrinsic subtypes of breast cancer.
    Lancet Oncol. 2010 Aug;11(8):718-9; author reply 720-1 PMID: 20688274
  77. Genomic signatures to guide the use of chemotherapeutics.
    Nat Med. 2006 Nov;12(11):1294-300 PMID: 17057710
  78. Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer.
    J Clin Oncol. 2008 Mar 1;26(7):1186-7; author reply 1187-8 PMID: 18309960
  79. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer.
    Breast Cancer Res Treat. 2010 Feb;119(3):551-8 PMID: 19214742
  80. Breast cancer molecular subtypes respond differently to preoperative chemotherapy.
    Clin Cancer Res. 2005 Aug 15;11(16):5678-85 PMID: 16115903
  81. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer.
    J Clin Oncol. 2006 Apr 10;24(11):1665-71 PMID: 16505412
  82. Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.
    Breast Cancer Res. 2010;12(4):R63 PMID: 20712882
  83. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer.
    Clin Cancer Res. 2010 Nov 1;16(21):5222-32 PMID: 20837693
  84. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
    Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 PMID: 11553815
  85. PSMB7 is associated with anthracycline resistance and is a prognostic biomarker in breast cancer.
    Br J Cancer. 2010 Jan 19;102(2):361-8 PMID: 20010949
  86. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
    Cancer Res. 2009 May 15;69(10):4116-24 PMID: 19435916
  87. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.
    Genome Biol. 2007;8(8):R157 PMID: 17683518
  88. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer.
    Clin Cancer Res. 2010 Nov 1;16(21):5351-61 PMID: 20829329
  89. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.
    J Clin Oncol. 2008 Sep 1;26(25):4063-71 PMID: 18678838
  90. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer.
    J Natl Cancer Inst. 2006 Sep 6;98(17):1183-92 PMID: 16954471
  91. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Cancer Cell. 2004 Jun;5(6):607-16 PMID: 15193263
  92. Molecular forecasting of breast cancer: time to move forward with clinical testing.
    J Clin Oncol. 2006 Feb 1;24(4):721-2; author reply 722-3 PMID: 16446348
  93. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade.
    J Pathol. 2010 Jan;220(2):263-80 PMID: 19927298
  94. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.
    Ann Oncol. 2009 Aug;20(8):1319-29 PMID: 19535820
  95. A gene-expression signature as a predictor of survival in breast cancer.
    N Engl J Med. 2002 Dec 19;347(25):1999-2009 PMID: 12490681
  96. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer.
    J Clin Oncol. 2006 Sep 10;24(26):4236-44 PMID: 16896004
  97. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
    Lancet Oncol. 2010 Jan;11(1):55-65 PMID: 20005174
  98. Repeatability of published microarray gene expression analyses.
    Nat Genet. 2009 Feb;41(2):149-55 PMID: 19174838
  99. Gene-expression signatures in breast cancer.
    N Engl J Med. 2009 Feb 19;360(8):790-800 PMID: 19228622
  100. Genomic grade index is associated with response to chemotherapy in patients with breast cancer.
    J Clin Oncol. 2009 Jul 1;27(19):3185-91 PMID: 19364972
  101. A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer.
    Breast Cancer Res. 2010;12(5):R85 PMID: 20946665
  102. Molecular subtypes in breast cancer evaluation and management: divide and conquer.
    Cancer Invest. 2008 Feb;26(1):1-10 PMID: 18181038
  103. Gene-expression-based prognostic assays for breast cancer.
    Nat Rev Clin Oncol. 2010 Jun;7(6):340-7 PMID: 20440284
  104. Development of the 21-gene assay and its application in clinical practice and clinical trials.
    J Clin Oncol. 2008 Feb 10;26(5):721-8 PMID: 18258979
  105. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors in early stage breast cancer.
    Clin Cancer Res. 2008 May 1;14(9):2601-8 PMID: 18451222
  106. Breast cancer molecular profiling with single sample predictors: a retrospective analysis.
    Lancet Oncol. 2010 Apr;11(4):339-49 PMID: 20181526
  107. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen.
    Oncogene. 2006 Jun 29;25(28):3994-4008 PMID: 16491124
  108. Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response.
    Breast Cancer Res Treat. 2010 Jan;119(1):119-26 PMID: 19669409
  109. The molecular portraits of breast tumors are conserved across microarray platforms.
    BMC Genomics. 2006 Apr 27;7:96 PMID: 16643655
  110. Microarrays: retracing steps.
    Nat Med. 2007 Nov;13(11):1276-7; author reply 1277-8 PMID: 17987014
  111. Genomics and the continuum of cancer care.
    N Engl J Med. 2011 Jan 27;364(4):340-50 PMID: 21268726
Article Info
Journal
Breast cancer research : BCR
Abbr.
Breast Cancer Res
ISSN
1465-542X
DOI
10.1186/bcr2890
Published
2011-06-27
Epub
2011-00-27
Pages
212
Language
English
Region
England
NLM ID
100927353
PMCID
PMC3218943
Subset
IM
Grants
Cancer Research UK · United Kingdom
External Links
PubMed source DOI: 10.1186/bcr2890 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2